118 related articles for article (PubMed ID: 11004568)
1. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors.
Mann WR; Dragland CJ; Vinluan CC; Vedananda TR; Bell PA; Aicher TD
Biochim Biophys Acta; 2000 Jul; 1480(1-2):283-92. PubMed ID: 11004568
[TBL] [Abstract][Full Text] [Related]
2. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase.
Korotchkina LG; Sidhu S; Patel MS
Free Radic Res; 2004 Oct; 38(10):1083-92. PubMed ID: 15512796
[TBL] [Abstract][Full Text] [Related]
3. Histidine modifying agents abolish pyruvate dehydrogenase kinase activity.
Mooney BP; David NR; Thelen JJ; Miernyk JA; Randall DD
Biochem Biophys Res Commun; 2000 Jan; 267(2):500-3. PubMed ID: 10631090
[TBL] [Abstract][Full Text] [Related]
4. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
[TBL] [Abstract][Full Text] [Related]
5. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase.
Korotchkina LG; Patel MS
J Biol Chem; 2001 Oct; 276(40):37223-9. PubMed ID: 11486000
[TBL] [Abstract][Full Text] [Related]
6. Nematode pyruvate dehydrogenase kinases: role of the C-terminus in binding to the dihydrolipoyl transacetylase core of the pyruvate dehydrogenase complex.
Chen W; Komuniecki PR; Komuniecki R
Biochem J; 1999 Apr; 339 ( Pt 1)(Pt 1):103-9. PubMed ID: 10085233
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
8. Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex.
Tuganova A; Boulatnikov I; Popov KM
Biochem J; 2002 Aug; 366(Pt 1):129-36. PubMed ID: 11978179
[TBL] [Abstract][Full Text] [Related]
9. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer.
Roche TE; Hiromasa Y
Cell Mol Life Sci; 2007 Apr; 64(7-8):830-49. PubMed ID: 17310282
[TBL] [Abstract][Full Text] [Related]
10. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP.
Bao H; Kasten SA; Yan X; Roche TE
Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
Tso SC; Qi X; Gui WJ; Wu CY; Chuang JL; Wernstedt-Asterholm I; Morlock LK; Owens KR; Scherer PE; Williams NS; Tambar UK; Wynn RM; Chuang DT
J Biol Chem; 2014 Feb; 289(7):4432-43. PubMed ID: 24356970
[TBL] [Abstract][Full Text] [Related]
12. The carboxy-terminal tail of pyruvate dehydrogenase kinase 2 is required for the kinase activity.
Klyuyeva A; Tuganova A; Popov KM
Biochemistry; 2005 Oct; 44(41):13573-82. PubMed ID: 16216081
[TBL] [Abstract][Full Text] [Related]
13. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites.
Kolobova E; Tuganova A; Boulatnikov I; Popov KM
Biochem J; 2001 Aug; 358(Pt 1):69-77. PubMed ID: 11485553
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer.
Stacpoole PW
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059435
[TBL] [Abstract][Full Text] [Related]
16. Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate.
Li J; Kato M; Chuang DT
J Biol Chem; 2009 Dec; 284(49):34458-67. PubMed ID: 19833728
[TBL] [Abstract][Full Text] [Related]
17. Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.
Zhou X; Yu S; Su J; Sun L
Int J Mol Sci; 2016 Mar; 17(3):340. PubMed ID: 26959013
[TBL] [Abstract][Full Text] [Related]
18. Global view of cognate kinase activation by the human pyruvate dehydrogenase complex.
Guevara EL; Yang L; Birkaya B; Zhou J; Nemeria NS; Patel MS; Jordan F
Sci Rep; 2017 Feb; 7():42760. PubMed ID: 28230160
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
Wu DM; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Chen GQ; Zheng YL
Eur J Med Chem; 2019 Feb; 164():252-262. PubMed ID: 30597326
[TBL] [Abstract][Full Text] [Related]
20. Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation.
Gan L; Yang Y; Liang Z; Zhang M; He Y; Zhang SL
Eur J Med Chem; 2024 Jan; 264():116008. PubMed ID: 38056298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
